Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
作者： Joachim Stangier , Sebastian Haertter , Karl-Heinz Liesenfeld , Wolfgang Wienen , Martin Feuring
DOI: 10.1160/TH09-11-0758
关键词: Anesthesia 、 Thrombin time 、 Pharmacology 、 Dabigatran 、 Direct thrombin inhibitor 、 Andexanet alfa 、 Ecarin clotting time 、 Medicine 、 Prothrombin time 、 Partial thromboplastin time 、 Idarucizumab
摘要: … Dabigatran etexilate is an oral, reversible direct thrombin inhibitor that is approved in the EU and several other countries for the prevention of venous thromboembolism after elective hip …
schattauer.de
wbs.cz 参考文章(43)
Steven V. Manoukian, Frederick Feit, Roxana Mehran, Michele D. Voeltz, Ramin Ebrahimi, Martial Hamon, George D. Dangas, A. Michael Lincoff, Harvey D. White, Jeffrey W. Moses, Spencer B. King, E. Magnus Ohman, Gregg W. Stone, Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial Journal of the American College of Cardiology. ,vol. 49, pp. 1362- 1368 ,(2007) , 10.1016/J.JACC.2007.02.027
D. Haverkamp, B. A. Hutten, H. R. Büller, A. S. Gallus, A. W. A. Lensing, M. H. Prins, The use of specific antidotes as a response to bleeding complications during anticoagulant therapy for venous thromboembolism. Journal of Thrombosis and Haemostasis. ,vol. 1, pp. 69- 73 ,(2003) , 10.1046/J.1538-7836.2003.00006.X
Stefan C. Carlsson, Christer Mattsson, Ulf G. Eriksson, Troy C. Sarich, Karin Wåhlander, Åsa Eliasson, Björn W. Karlson, Sunita B. Sheth, Peter Held, A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays. Thrombosis Research. ,vol. 115, pp. 9- 18 ,(2005) , 10.1016/J.THROMRES.2004.07.001
Michael D. Ezekowitz, Paul A. Reilly, Gerhard Nehmiz, Timothy A. Simmers, Rangadham Nagarakanti, Kambiz Parcham-Azad, K. Erik Pedersen, Dominick A. Lionetti, Joachim Stangier, Lars Wallentin, Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). American Journal of Cardiology. ,vol. 100, pp. 1419- 1426 ,(2007) , 10.1016/J.AMJCARD.2007.06.034
Sunil V. Rao, Kristi O’Grady, Karen S. Pieper, Christopher B. Granger, L. Kristin Newby, Frans Van de Werf, Kenneth W. Mahaffey, Robert M. Califf, Robert A. Harrington, Impact of Bleeding Severity on Clinical Outcomes Among Patients With Acute Coronary Syndromes American Journal of Cardiology. ,vol. 96, pp. 1200- 1206 ,(2005) , 10.1016/J.AMJCARD.2005.06.056
Susanne Johansson, Karin Wåhlander, Göran Larson, Lis Ohlsson, Marita Larsson, Ulf G Eriksson, Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men. Blood Coagulation & Fibrinolysis. ,vol. 14, pp. 677- 684 ,(2003) , 10.1097/00001721-200310000-00010
Bengt I Eriksson, Daniel J Quinlan, Jeffrey I Weitz, Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development Clinical Pharmacokinectics. ,vol. 48, pp. 1- 22 ,(2009) , 10.2165/0003088-200948010-00001
Jennifer J Oh, Wendell S Akers, Daniel Lewis, Chand Ramaiah, Jeremy D Flynn, Recombinant factor VIIa for refractory bleeding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor lepirudin. Pharmacotherapy. ,vol. 26, pp. 576- 577 ,(2006) , 10.1592/PHCO.26.4.576
Joachim Stangier, Hildegard Stähle, Karin Rathgen, Reinhold Fuhr, Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clinical Pharmacokinectics. ,vol. 47, pp. 47- 59 ,(2008) , 10.2165/00003088-200847010-00005
Mark A. Crowther, Theodore E. Warkentin, Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood. ,vol. 111, pp. 4871- 4879 ,(2008) , 10.1182/BLOOD-2007-10-120543